Endoscopic treatment of vesicoureteral reflux using dextranomer hyaluronic acid copolymer.
Vesicoureteral reflux (VUR) is a common urinary tract anomaly. Treatment is performed to minimize the risk of febrile urinary UTIs that may result in renal scarring. The endoscopic use of dextranomer hyaluronic acid copolymer has been gaining popularity as an alternative to the traditional methods of open surgery and chronic antibiotic prophylaxis. The aim of this educational review was to present the trends, latest perspectives and surgical techniques regarding this newer method of treatment of VUR. Evolving techniques are described that have resulted in VUR cure rates that rival that of open ureteral reimplantation with minimal associated morbidity. These have proven to be effective in complex cases that were previously considered as contraindications for endoscopic treatment, including voiding dysfunction, duplex ureters, high-grade VUR and paraureteral diverticuli. It is recommended that open reimplantation be reserved for those children with ectopic ureters, megaureters that require tapering or secondary grade V VUR, and those who have failed two endoscopic injections. Future advances promise to standardize the injection technique, ensuring optimum needle placement for consistently successful injections.
Molitierno
Joseph A
JA
Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30342, USA. jmolitierno@gmail.com
Scherz
Hal C
HC
Kirsch
Andrew J
AJ
D002648:Child; D003558:Cystoscopy / Q000379:methods*; D003911:Dextrans / Q000008:administration & dosage*; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage*; D019919:Prosthesis Implantation / Q000379:methods*; D016896:Treatment Outcome; D014718:Vesico-Ureteral Reflux / Q000601:surgery*
D003911:Dextrans; C487487:dextranomer-hyaluronic acid copolymer; D006820:Hyaluronic Acid